FCF Biotech Venture Capital Monitor – USA 08/2023 published

FCF Fox Corporate Finance GmbH is delighted to publish the new “FCF Biotech Venture Capital Monitor – USA 08/2023”.

The Monitor is a monthly published overview of venture capital trends in the US-Biotech sector.

As of the end of August 2023, we identify the following current VC trends in the US-Biotech sector:

  • In 2023, overall Biotech funding in the USA has reached USD 13,752m
  • Compared to August 2022 the financing volume decreased by more than 40% (23,189m vs. 13,752m)
  • The top 5 deals exceed USD 270m each, the largest transaction amounted to USD 401m with ElevateBio
  • Cellares has the highest transaction Volume of USD 255m in August, followed by Genesis Therapeutics USD 224m and ADARx Pharmaceuticals USD 200m
  • Flagship Pioneers (USA) is leading the Top 5 Investors (by deal volume), followed by ARCH Venture Partners (USA) and OrbiMed (USA)
  • As an indication oncology records the highest investment activity

To access the full report, please click here.

By Mathias Klozenbücher, Johannes Link and Marcel-Louis Christou.